Skip to main content
. 2018 Oct 28;24(40):4548–4553. doi: 10.3748/wjg.v24.i40.4548

Table 1.

Regimens for second-line anti-Helicobacter pylori therapy

Regimen Drug
Duration of therapy
PPI Bismuth Levo Amox Tetra Metro
Bismuth-containing quadruple therapy SD, b.i.d. 120 mg, q.i.d. 500 mg, q.i.d. 500 mg, t.i.d. 10-14 d
Levofloxacin-containing triple therapy SD, b.i.d. 500 mg, q.d. 1 g, b.i.d. 10-14 d
Levofloxacin-amoxicillin quadruple therapy SD, b.i.d. 120 mg, q.i.d. 500 mg, q.d. 1 g, b.i.d. 10-14 d
Tetracycline-levofloxacin quadruple therapy SD, b.i.d. 120 mg, q.i.d. 500 mg, q.d. 500 mg, q.i.d. 10 d
High-dose dual therapy SD, q.i.d. 750 mg, b.i.d. 14 d

PPI: Proton pump inhibitor; Levo: Levofloxacin; Amox: Amoxicillin; Tetra: Tetracycline; Metro: Metronidazole.

HHS Vulnerability Disclosure